Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes
- 1 January 1988
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 37 (1) , 28-32
- https://doi.org/10.2337/diabetes.37.1.28
Abstract
In this study the effect of two drugs [etomoxir and nicotinic acid (NA)] on plasma glucose, free–fatty acid (FFA), and triglyceride (TG) concentrations was determined in rats with streptozocin (STZ)-induced diabetes. The two compounds modify FFA metabolism by different mechanisms, etomoxir (ethyl-2-[6-(4-cholorophenoxyl)-hexyl]oxirane-2-carboxylate) by inhibiting hepatic fatty acid oxidation, and NA by inhibiting lipolysis in adipose tissue. Diabetes was induced in male Sprague-Dawley rats, weighing ∼ 400 g, by STZ injection (30 mg/kg i.v.), and the metabolic effects of the two drugs were studied 7–10 days later. The acute administration of either etomoxir or NA lowered plasma glucose concentrations in diabetic rats by ∼150 mg/dl (P < .001) in 4 h. However, the two drugs differed dramatically in their effects on plasma FFA and TG concentrations. Specifically, etomoxir produced striking increases in plasma FFA and TG concentrations, whereas NA administration caused a marked decrease. However, when NA was given in conjunction with etomoxir, NA prevented the increase in plasma FFA and TG concentration seen with etomoxir; the combination of NA and etomoxir approximately doubled the decrease in plasma glucose concentration produced by NA or etomoxir when given alone. Because plasma insulin concentrations did not change in response to either drug, whether administered singly or in combination, these metabolic effects do not result from a change in insulin secretion. These results suggest that modulation of FFA metabolism at the level of the adipocyte or the liver can have dramatic effects on carbohydrate and lipid metabolism. Also, NA prevented the potentially adverse effects that etomoxir had on FFA and TG. The observation that the two drugs given in combination were capable of lowering plasma glucose from <400 mg/dl to essentially normal levels within 4 h raises the possibility that this pharmacologic approach may have relevance to the treatment of diabetes.This publication has 13 references indexed in Scilit:
- Ambient Plasma Free Fatty Acid Concentrations in Noninsulin-Dependent Diabetes Mellitus: Evidence for Insulin Resistance*Journal of Clinical Endocrinology & Metabolism, 1985
- α-Ketoacid dehydrogenase complexes and respiratory fuel utilisation in diabetesDiabetologia, 1985
- Decrease of fatty acid oxidation, ketogenesis and gluconeogenesis in isolated perfused rat liver by phenylalkyl oxirane carboxylate (B 807‐27) due to inhibition of CPT I (EC 2.3.1.21)European Journal of Biochemistry, 1985
- Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects.Journal of Clinical Investigation, 1984
- Insulin resistance in older ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 1984
- Influence of hyperglycemia on insulin's in vivo effects in type II diabetes.Journal of Clinical Investigation, 1984
- Phenylalkyloxirane carboxylic acids, a new class of hypoglycaemic substances: Hypoglycaemic and hypoketonaemic effects of sodium 2-[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate (B 807-27) in fasted animalsDiabetologia, 1982
- Evidence for multiple causality in the development of diabetic hypertriglyceridaemiaDiabetologia, 1980
- Methyl 2-Tetradecylglycidate, An Orally Effective Hypoglycemic Agent that Inhibits Long Chain Fatty Acid Oxidation SelectivelyDiabetes, 1979
- Pharmacologic profile of methyl 2-tetradecylglycidate (McN-3716)—An orally effective hypoglycemic agentMetabolism, 1978